Vanguard Asset Management
CRSP icon

Vanguard Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Vanguard Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.72M Buy
86,550
+9,688
+13% +$511K ﹤0.01% 1079
2026
Q1 		$3.66M Buy
+76,862
New +$4.05M ﹤0.01% 1122

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Asset Management's CRSP Position: Q2 2026 in Review

Vanguard Asset Management increased its CRISPR Therapeutics (CRSP) stake by 13% in Q2 2026, buying an estimated $511K and bringing the position to 86,550 shares worth $4.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1079.

Vanguard Asset Management first reported a position in CRSP in Q1 2026 and has held it in 2 quarters since. 506 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Vanguard Asset Management held 86,550 shares of CRISPR Therapeutics worth $4.72M as of Q2 2026.
  • Vanguard Asset Management bought 9,688 CRISPR Therapeutics shares in Q2 2026, an estimated $511K.
  • CRISPR Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1079 holding.
  • Vanguard Asset Management first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 506 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.